Skip to main content
SpringerLink
Log in

Esophageal Cancer

  • Chapter
  • First Online:
Surgical Oncology Manual

  • 823 Accesses

Abstract

Esophageal cancer is an aggressive disease with increasing incidence in the Western population. Histologic incidence is defined geographically by a predominance of squamous cell carcinoma in Eastern countries and South America, whereas adenocarcinoma is by far the main histologic type in Western countries including Oceania. The risk factors are unique for each of these histologic types.

The development of effective neoadjuvant regimens based on chemoradiation or chemotherapy and surgery has defined a trimodal approach as standard of care. This has allowed better locoregional control and better disease-specific and overall survival compared to surgery alone.

Patient selection, tailored multimodal approach defined by cancer biology and stage, and new minimally invasive surgical approaches have reduced perioperative morbidity and mortality.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Malhotra GK, Yanala U, Ravipati A, Follet M, Vijayakumar M, Are C. Global trends in esophageal cancer. J Surg Oncol. 2017;115(5):564–79.

    Article  PubMed  Google Scholar 

  2. DaVee T, Ajani JA, Lee JH. Is endoscopic ultrasound examination necessary in the management of esophageal cancer? World J Gastroenterol. 2017;23(5):751–62.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Napier KJ, Scheerer M, Misra S. Esophageal cancer: a review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol. 2014;6(5):112–20.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.

    Article  CAS  PubMed  Google Scholar 

  5. Prabhu A, Obi KO, Rubenstein JH. The synergistic effects of alcohol and tobacco consumption on the risk of esophageal squamous cell carcinoma: a meta-analysis. Am J Gastroenterol. 2014;109(6):822–7.

    Article  PubMed  Google Scholar 

  6. Lm S, Ep Q, Rh W. The next wave: confexting. J Digit Imaging. 2012;25(1):25–9.

    Article  PubMed  Google Scholar 

  7. Brown LM, Devesa SS, Chow WH. Incidence of adenocarcinoma of the esophagus among white Americans by sex, stage, and age. J Natl Cancer Inst. 2008;100(16):1184–7.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Mao WM, Zheng WH, Ling ZQ. Epidemiologic risk factors for esophageal cancer development. Asian Pac J Cancer Prev. 2011;12(10):2461–6.

    PubMed  Google Scholar 

  9. Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM. Preoperative prevalence of Barrett's esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology. 2002;122(1):26–33.

    Article  PubMed  Google Scholar 

  10. Shin A, Won YJ, Jung HK, Kong HJ, Jung KW, Oh CM, et al. Trends in incidence and survival of esophageal cancer in Korea: analysis of the Korea Central Cancer Registry Database. J Gastroenterol Hepatol. 2018;33(12):1961–8.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Patel N, Benipal B. Incidence of esophageal cancer in the United States from 2001–2015: a United States cancer statistics analysis of 50 states. Cureus. 2018;10(12):e3709.

    PubMed  PubMed Central  Google Scholar 

  12. Hur C, Miller M, Kong CY, Dowling EC, Nattinger KJ, Dunn M, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer. 2013;119(6):1149–58.

    Article  PubMed  Google Scholar 

  13. Romagnuolo J, Scott J, Hawes RH, Hoffman BJ, Reed CE, Aithal GP, et al. Helical CT versus EUS with fine needle aspiration for celiac nodal assessment in patients with esophageal cancer. Gastrointest Endosc. 2002;55(6):648–54.

    Article  PubMed  Google Scholar 

  14. Flamen P. Positron emission tomography in gastric and esophageal cancer. Curr Opin Oncol. 2004;16(4):359–63.

    Article  PubMed  Google Scholar 

  15. Stahl A, Ott K, Weber WA, Becker K, Link T, Siewert JR, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging. 2003;30(2):288–95.

    Article  CAS  PubMed  Google Scholar 

  16. Kim K, Park SJ, Kim BT, Lee KS, Shim YM. Evaluation of lymph node metastases in squamous cell carcinoma of the esophagus with positron emission tomography. Ann Thorac Surg. 2001;71(1):290–4.

    Article  CAS  PubMed  Google Scholar 

  17. Flamen P, Lerut A, Van Cutsem E, De Wever W, Peeters M, Stroobants S, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol. 2000;18(18):3202–10.

    Article  CAS  PubMed  Google Scholar 

  18. Schroer-Gunther M, Scheibler F, Wolff R, Westwood M, Baumert B, Lange S. The role of PET and PET-CT scanning in assessing response to neoadjuvant therapy in esophageal carcinoma. Dtsch Arztebl Int. 2015;112(33–34):545–52.

    PubMed  PubMed Central  Google Scholar 

  19. Rice TW, Gress DM, Patil DT, Hofstetter WL, KelsenDP, Blackstone EH. Cancer of the esophagus and esophagogastric junction- Major changes in the American Joint Committee on Cancer eight edition cancer staging manual. Ca Cancer J Clin. 2017;67:304–17. https://doi.org/10.332/caac.21399.

  20. Wei WI, Lam LK, Yuen PW, Wong J. Current status of pharyngolaryngo-esophagectomy and pharyngogastric anastomosis. Head Neck. 1998;20(3):240–4.

    Article  CAS  PubMed  Google Scholar 

  21. Tong DK, Law S, Kwong DL, Wei WI, Ng RW, Wong KH. Current management of cervical esophageal cancer. World J Surg. 2011;35(3):600–7.

    Article  PubMed  Google Scholar 

  22. Higuchi K, Koizumi W, Tanabe S, Sasaki T, Katada C, Azuma M, et al. Current management of esophageal squamous-cell carcinoma in Japan and other countries. Gastrointest Cancer Res. 2009;3(4):153–61.

    PubMed  PubMed Central  Google Scholar 

  23. Katada C, Muto M, Manabe T, Boku N, Ohtsu A, Yoshida S. Esophageal stenosis after endoscopic mucosal resection of superficial esophageal lesions. Gastrointest Endosc. 2003;57(2):165–9.

    Article  PubMed  Google Scholar 

  24. Kato H, Sato A, Fukuda H, Kagami Y, Udagawa H, Togo A, et al. A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol. 2009;39(10):638–43.

    Article  PubMed  Google Scholar 

  25. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19(2):305–13.

    Article  CAS  PubMed  Google Scholar 

  26. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002;359(9319):1727–33.

    Article  Google Scholar 

  27. Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, et al. Long-term results of RTOG trial 8911 (USA intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007;25(24):3719–25.

    Article  PubMed  Google Scholar 

  28. Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–8.

    Article  PubMed  Google Scholar 

  29. Lerut T, Nafteux P, Moons J, Coosemans W, Decker G, De Leyn P, et al. Three-field lymphadenectomy for carcinoma of the esophagus and gastroesophageal junction in 174 R0 resections: impact on staging, disease-free survival, and outcome. Ann Surg. 2004;240(6):962–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Li B, Xiang J, Zhang Y, Li H, Zhang J, Sun Y, et al. Comparison of Ivor-Lewis vs Sweet esophagectomy for esophageal squamous cell carcinoma: a randomized clinical trial. JAMA Surg. 2015;150(4):292–8.

    Article  PubMed  Google Scholar 

  31. Karstens KF, Izbicki JR, Reeh M. Does the margin matter in esophageal cancer. Dig Surg. 2018;35(3):196–203.

    Article  PubMed  Google Scholar 

  32. Pennathur A, Gibson MK, Jobe BA, Luketich JD. Oesophageal carcinoma. Lancet. 2013;381(9864):400–12.

    Article  PubMed  Google Scholar 

  33. Sagar PM, Johnston D, McMahon MJ, Dixon MF, Quirke P. Significance of circumferential resection margin involvement after oesophagectomy for cancer. Br J Surg. 1993;80(11):1386–8.

    Article  CAS  PubMed  Google Scholar 

  34. Chao YK, Yeh CJ, Chang HK, Tseng CK, Chu YY, Hsieh MJ, et al. Impact of circumferential resection margin distance on locoregional recurrence and survival after chemoradiotherapy in esophageal squamous cell carcinoma. Ann Surg Oncol. 2011;18(2):529–34.

    Article  PubMed  Google Scholar 

  35. Rizk NP, Ishwaran H, Rice TW, Chen LQ, Schipper PH, Kesler KA, et al. Optimum lymphadenectomy for esophageal cancer. Ann Surg. 2010;251(1):46–50.

    Article  PubMed  Google Scholar 

  36. Kato K, Muro K, Minashi K, Ohtsu A, Ishikura S, Boku N, et al. Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II-III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys. 2011;81(3):684–90.

    Article  CAS  PubMed  Google Scholar 

  37. Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25(10):1160–8.

    Article  CAS  PubMed  Google Scholar 

  38. Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17(9):2915–21.

    Article  CAS  PubMed  Google Scholar 

  39. Ishida K, Ando N, Yamamoto S, Ide H, Shinoda M. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol. 2004;34(10):615–9.

    Article  PubMed  Google Scholar 

  40. Higuchi K, Komori S, Tanabe S, Katada C, Azuma M, Ishiyama H, et al. Definitive chemoradiation therapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) in advanced esophageal cancer: a phase 2 trial (KDOG 0501-P2). Int J Radiat Oncol Biol Phys. 2014;89(4):872–9.

    Article  CAS  PubMed  Google Scholar 

  41. Makino T. DY. Treatment of T4 esophageal cancer. Definitive chemo-radiotherapy vs chemo-radiotherapy followed by surgery. Ann Thorac Cardiovasc Surg. 2011;17(3):221–8.

    Article  PubMed  Google Scholar 

  42. Tahara M, Minami H, Hasegawa Y, Tomita K, Watanabe A, Nibu K, et al. Weekly paclitaxel in patients with recurrent or metastatic head and neck cancer. Cancer Chemother Pharmacol. 2011;68(3):769–76.

    Article  CAS  PubMed  Google Scholar 

  43. Homs MY, Steyerberg EW, Eijkenboom WM, Tilanus HW, Stalpers LJ, Bartelsman JF, et al. Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet. 2004;364(9444):1497–504.

    Article  PubMed  Google Scholar 

  44. Bergquist H, Wenger U, Johnsson E, Nyman J, Ejnell H, Hammerlid E, et al. Stent insertion or endoluminal brachytherapy as palliation of patients with advanced cancer of the esophagus and gastroesophageal junction. Results of a randomized, controlled clinical trial. Dis Esophagus. 2005;18(3):131–9.

    Article  CAS  PubMed  Google Scholar 

  45. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.

    Article  CAS  PubMed  Google Scholar 

  46. Al-Batran S-E, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet. 2019;393(10184):1948–57.

    Article  PubMed  Google Scholar 

  47. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27(6):851–6.

    Article  CAS  PubMed  Google Scholar 

  48. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.

    Article  CAS  PubMed  Google Scholar 

  49. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–35.

    Article  CAS  PubMed  Google Scholar 

  50. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383(9911):31–9.

    Article  CAS  PubMed  Google Scholar 

  51. Raufi AG, Klempner SJ. Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. J Gastrointest Oncol. 2015;6(5):561–9.

    PubMed  PubMed Central  Google Scholar 

  52. Rice TW, Kelsen DP, Blackstone EH, Ishwaran H, Patil DT, Bass AJ, et al. Esophagus and esophagogastric junction. In: Amin MB, Edge SB, Greene FL, editors. AJCC Cancer staging manual. 8th ed. New York, NY: Springer; 2017. p. 185–202.

    Chapter  Google Scholar 

  53. Barbour AP, Rizk NP, Gonen M, Tang L, Bains MS, Rusch VW, et al. Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome. Ann Surg. 2007;246(1):1–8.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Hulscher JB, van Sandick JW, de Boer AG, Wijnhoven BP, Tijssen JG, Fockens P, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002;347(21):1662–9.

    Article  PubMed  Google Scholar 

  55. Omloo JM, Lagarde SM, Hulscher JB, Reitsma JB, Fockens P, van Dekken H, et al. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the mid/distal esophagus: five-year survival of a randomized clinical trial. Ann Surg. 2007;246(6):992–1000; discussion -1.

    Article  PubMed  Google Scholar 

  56. Sasako M, Sano T, Yamamoto S, Sairenji M, Arai K, Kinoshita T, et al. Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol. 2006;7(8):644–51.

    Article  PubMed  Google Scholar 

  57. Dresner SM, Lamb PJ, Bennett MK, Hayes N, Griffin SM. The pattern of metastatic lymph node dissemination from adenocarcinoma of the esophagogastric junction. Surgery. 2001;129(1):103–9.

    Article  CAS  PubMed  Google Scholar 

  58. Pedrazzani C, de Manzoni G, Marrelli D, Giacopuzzi S, Corso G, Minicozzi AM, et al. Lymph node involvement in advanced gastroesophageal junction adenocarcinoma. J Thorac Cardiovasc Surg. 2007;134(2):378–85.

    Article  PubMed  Google Scholar 

  59. Kurokawa Y, Sasako M, Sano T, Yoshikawa T, Iwasaki Y, Nashimoto A, et al. Ten-year follow-up results of a randomized clinical trial comparing left thoracoabdominal and abdominal transhiatal approaches to total gastrectomy for adenocarcinoma of the oesophagogastric junction or gastric cardia. Br J Surg. 2015;102(4):341–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Lagergren J, Mattsson F, Zylstra J, Chang F, Gossage J, Mason R, et al. Extent of lymphadenectomy and prognosis after esophageal cancer surgery. JAMA Surg. 2016;151(1):32–9.

    Article  PubMed  Google Scholar 

  61. Biere SS, van Berge Henegouwen MI, Maas KW, Bonavina L, Rosman C, Garcia JR, et al. Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet. 2012;379(9829):1887–92.

    Article  PubMed  Google Scholar 

  62. Dantoc M, Cox MR, Eslick GD. Evidence to support the use of minimally invasive esophagectomy for esophageal cancer: a meta-analysis. Arch Surg. 2012;147(8):768–76.

    Article  PubMed  Google Scholar 

  63. Burdall OC, Boddy AP, Fullick J, Blazeby J, Krysztopik R, Streets C, et al. A comparative study of survival after minimally invasive and open oesophagectomy. Surg Endosc. 2015;29(2):431–7.

    Article  PubMed  Google Scholar 

  64. Bongiolatti S, Annecchiarico M, Di Marino M, Boffi B, Borgianni S, Gonfiotti A, et al. Robot-sewn Ivor-Lewis anastomosis: preliminary experience and technical details. Int J Med Robot. 2016;12(3):421–6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Complex General Surgical Oncology, University of Toronto, Toronto, ON, Canada

    Nicolas Devaud

  2. General Surgery Resident, University of Toronto, Toronto, ON, Canada

    Vaibhav Gupta

  3. Department of Surgery, University of Toronto, Toronto, ON, Canada

    Eran Shlomovitz, Jonathan C. Yeung, Michael Ko & Gail Darling

Authors
  1. Nicolas Devaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vaibhav Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eran Shlomovitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jonathan C. Yeung
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael Ko
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gail Darling
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gail Darling .

Editor information

Editors and Affiliations

  1. Department of Surgery, University of Toronto, Toronto, ON, Canada

    Frances C. Wright

  2. Department of Surgery, University of Toronto, Toronto, ON, Canada

    Jaime M. Escallon

  3. Department of Surgery, University of Toronto, Toronto, ON, Canada

    Moises Cukier

  4. Department of Surgery, University of Toronto, Toronto, ON, Canada

    Melanie E. Tsang

  5. Department of Surgery, University of Toronto, Toronto, ON, Canada

    Usmaan Hameed

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Devaud, N., Gupta, V., Shlomovitz, E., Yeung, J.C., Ko, M., Darling, G. (2020). Esophageal Cancer. In: Wright, F., Escallon, J., Cukier, M., Tsang, M., Hameed, U. (eds) Surgical Oncology Manual. Springer, Cham. https://doi.org/10.1007/978-3-030-48363-0_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-48363-0_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-48362-3

  • Online ISBN: 978-3-030-48363-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation